Cixutumumab

Kevin P. McKian, Paul Haluska

Research output: Contribution to journalReview article

46 Scopus citations

Abstract

The IGF pathway plays a major role in cancer cell proliferation, survival and resistance to antineoplastic therapies in many human malignancies. As such, interference with this pathway is the target of many investigational pharmacologic agents. Cixutumumab, a monoclonal antibody to IGF-1R, utilizes this concept. In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers.

Original languageEnglish (US)
Pages (from-to)1025-1033
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number7
DOIs
StatePublished - Jul 2009

Keywords

  • Cixutumumab
  • IGF-1R
  • IMC-A12
  • Monoclonal antibody

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cixutumumab'. Together they form a unique fingerprint.

  • Cite this